Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
Thought Leadership
Latest Report
Access valuable insights on payer behaviour
During early-stage development, it has become more critical than ever to factor in payer perspectives and reimbursement dynamics. For a clearer understanding of the payer landscape across US healthcare download the infographic.
Report library
Medtech - Going steady
The medtech sector, like the wider pharma market, has been having a tough time. There are, however, glimmers of light and some interesting developments – including…
Pharma Drivers Ebook Part 2: Ch-ch-changes
2028-2029 will see some of the biggest blockbusters on the market lose their exclusivity with up to $115bn of sales at risk across those two years. Realistically, of…
Pharma Drivers eBook 1: Hey Big (Pharma) Spender
Big pharma spent £183bn on R&D, M&A and licensing deals in 2021. Huge though that figure is, it’s actually a slight dip in overall spend compared to the previous…
Vantage Top 10 Most Read Report
The Evaluate Vantage team has rounded up our Top 10 Most-Read stories. Get up to speed on the big issues that have captured the interest and attention of your peers and…
Asco 2022 eBook
Thousands of abstracts were submitted for the recent Asco meeting in Chicago and 40,000 oncology professionals gathered to delve into cutting-edge research,…
Q1 2022: Choppy Waters eBook
If the first quarter of 2022 was a bellwether for the rest of year, many in the drug development market might want to don wet weather gear and hunker down for a blustery…
Orphan Drug 2022 Report
Treatments for orphan indications and rare diseases are no longer a niche area of focus for developers. Orphan products have become one of the fastest growing areas of…
Genetic Medicine: The Next Generation
Huge investment in the first generation of genetic medicine led, by and large, to incredibly high valuations for companies, and before too long, some in the market began…
Orphan Drug 2022 Infographic
In 2021, over half of the FDA’s new drug approvals were for orphan or rare diseases. While orphan products are one of the fastest-growing areas of drug development, it…
PD(L)anner - March 2022
The Evaluate Vantage PD(L)anner – March 2022 provides news, insights and analysis on the PD-(L)1 antibody landscape. Among other issues, we focus on potential pricing…
